5-(4-aminophenyl)isoquinoline | 1044668-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-(4-aminophenyl)isoquinoline
• 英文别名: 4-isoquinolin-5-ylaniline
• CAS: 1044668-68-9
• 化学式: C₁₅H₁₂N₂
• mdl: MFCD17129391
• 分子量: 220.274
• InChiKey: PFDSZNDKLAZPJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-溴异喹啉 、 4-氨基苯硼酸频哪醇酯 生成 5-(4-aminophenyl)isoquinoline
  参考文献：
  名称：

  SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS

  摘要：

  化合物的化学式为（I）或其盐或溶剂化合物，其中： R1和R2中的一个是H，另一个表示为—NHCONHR4，其中R4表示苯基或萘基，可以选择地由一个或多个取代基独立选择从—C1-6烷基，—C1-6卤代烷基，卤素，C1-6烷氧基，C1-6卤代烷氧基，OH，NO2，C3-7环烷基，吲哚基或R4与其连接的NH形成吗啡环基；而R3是H或NHR5，其中R5是H，-喹啉基或-异喹啉基，—（CONH）pphenyl，其中p为0或1，苯基可以选择地由一个或多个取代基独立选择从卤素，—C1-6烷基，—C1-6卤代烷基，-吗啡环基，—SO2NH2和甲基取代苯并噻唑基。

  公开号：

  US20090291949A1

文献信息

• [EN] SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS<br/>[FR] ISOQUINOLINES SUBSTITUEES UTILES POUR LE TRAITEMENT DE MALADIES DU TYPE CANCER ET ATHEROSCLEROSE
  申请人：GLAXO GROUP LTD

  公开号：WO2005049576A1

  公开（公告）日：2005-06-02

  A compound of Formula (I) wherein: One of R1 and R2 is H and the other represents - NHCONHR4 wherein R4 represents a phenyl or naphthyl group (which may be optionally substituted by one or more substituents independently selected from -C1-6 alkyl, -C1-6 haloalkyl, - CH2CH2CH2-, halogen, C1-6 alkoxy, C1-6 haloalkoxy, OH, NO2), C3-7 cycloalkyl or R4 together with the NH to which it is bonded forms a morpholino group and R3 is H or NHR5 wherein R5 is H, -quinolinyl or -isoquinolinyl, -(CONH)p phenyl (wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C1-6 alkyl, -C1-6 haloalkyl, -morpholino, -SO2NH2, benzothiazole (substituted by methyl)) or a salt, solvate, or physiologically functional derivative thereof.

  根据公式(I)的化合物，其中：R1和R2之一是H，另一个代表-NHCONHR4，其中R4代表一个苯基或萘基团（可以任选地被一个或多个独立选自-C1-6烷基，-C1-6卤代烷基，-CH2CH2CH2-，卤素，C1-6烷氧基，C1-6卤代烷氧基，OH，NO2的取代基所取代），C3-7环烷基或R4与它所连接的NH形成一个吗啉基团，并且R3是H或NHR5，其中R5是H，-喹啉基或-异喹啉基，-(CONH)p苯基（其中p是0或1，并且苯基可以任选地被一个或多个独立选自卤素，-C1-6烷基，-C1-6卤代烷基，-吗啉基，-SO2NH2，苯并噻唑（被甲基取代）的取代基所取代）或其盐，溶剂化物，或生理功能衍生物。
• Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：US11471538B2

  公开（公告）日：2022-10-18

  The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of 10 SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of 15 SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6.

  癌症患者对 MAPK 抑制剂的反应因继发性抗药性和快速复发而大打折扣。迄今为止，驱动这些抗药性的分子机制尚不完全清楚。本发明人发现，MAPK 抑制剂（如 Vemurafenib）会诱导 10 SLITRK6（SLIT 和 NTRK 样家族，成员 6）的表达，在 MAPK 抑制剂存在的情况下抑制其诱导会诱导合成致死。因此，只有通过抑制 SLITRK6 的活性或表达，才能增强 MAPK 抑制剂的抗肿瘤效果，避免出现对这些化合物的抗药性。此外，SLITRK6 的特异性表达也为通过使用能够介导 ADCC 的抗 SLITRK6 抗体或与 SLITRK6 结合的抗体-药物共轭物靶向清除残余癌细胞的策略铺平了道路。
• SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1689717B1

  公开（公告）日：2007-12-26
• WOUND HEALING USING BRAF INHIBITORS
  申请人：The Regents of the University of California

  公开号：EP3139927A1

  公开（公告）日：2017-03-15
• STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO
  申请人：Tract Pharmaceuticals, Inc.

  公开号：EP3732285A1

  公开（公告）日：2020-11-04